Abstract
Abstract
Background
Buserelin is a luteinizing hormone releasing hormone (LHRH) agonist used for the treatment of hormone-dependent diseases in males and females. However, the pharmacokinetics of buserelin in pigs and cows are not fully understood. This study was designed to develop a sensitive method to determine the concentration of buserelin in blood plasma and to investigate the pharmacokinetic parameters after intramuscular (i.m.) administration in pigs and cows.
Results
A sensitive and rapid stability method based on ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed. The pharmacokinetic parameters of buserelin after i.m. administration were studied in five pigs and five cows at a single dose of 1 mg per pig and 3 mg per cow. The plasma kinetics were analyzed by WinNonlin 8.1.0 software using a non-compartmental model. The mean concentration area under the curve (AUC0-t) was 25.02 ± 6.93 h × ng/mL for pigs and 5.63 ± 1.86 h × ng/mL for cows. The maximum plasma concentration (Cmax) and time to reach the maximum concentration (tmax) were 10.99 ± 2.04 ng/mL and 0.57 ± 0.18 h for pigs and 2.68 ± 0.36 ng/mL and 1.05 ± 0.27 h for cows, respectively. The apparent volume of distribution (Vz) in pigs and cows was 80.49 ± 43.88 L and 839.88 ± 174.77 L, respectively. The elimination half-time (t1/2), and clearance (CL) were 1.29 ± 0.40 h and 41.15 ± 11.18 L/h for pigs and 1.13 ± 0.3 h and 545.04 ± 166.40 L/h for cows, respectively. No adverse effects were observed in any of the animals.
Conclusion
This study extends previous studies describing the pharmacokinetics of buserelin following i.m. administration in pigs and cows. Further studies investigating other factors were needed to establish therapeutic protocol in pigs and cows and to extrapolate these parameters to others economic animals.
Funder
Metabolic Return of Antimicrobial Drugs and Environmental Micro-ecological Rise Assessment Foundation of China
Anhui Province Key Laboratory of Livestock and Poultry Product Safety Engineering
Publisher
Springer Science and Business Media LLC
Subject
General Veterinary,General Medicine
Reference29 articles.
1. Buserelin summary report committee veterinary medicinal products https://www.ema.europa.eu/en/documents/mrl-report/buserelin-summary-report-committee-veterinary-medicinal-products_en.pdf.
2. Bruun E, Frimodt-Moller C. Buserelin (Suprefact). Ugeskr Laeger. 1986;148(36):2301–4.
3. Brogden RN, Buckley MM, Ward A. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile. Drugs. 1990;39(3):399–437.
4. Baumann KH, Kiesel L, Kaufmann M, Bastert G, Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat. 1993;25(1):37–46.
5. de Voogt HJ, Adenauer H, Widdra WG. The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents. Scand J Urol Nephrol Suppl. 1991;138:131–6.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献